
4
Helping you prosper
The Management Board provides for a possibility to exercise the right to authorize
Company’s share capital increase or finance its investment activities via alternative capital
instruments and/or financial support schemes funded by the European Union or domestically,
which could effectively help in financing the Company’s activities.
We believe that the possibility of implementing the adopted assumptions is uncertain;
although, it cannot be ruled out that due to unforeseen costs or unforeseen reduction in the
rate of acquiring customers and revenues, increasing the demand for funding in each case,
the Company’s financial standing will significantly deviate from the assumptions, which may
adversely impact the Company’s operations, growth prospects, financial standing or results.
Our opinion does not include any modification in this regard.
Key audit matters
Key audit matters are issues that, as per our professional judgement, were of highest
significance in our audit of the separate financial statement for the current reporting period.
These include the most significant of the assessed material misstatement risk, including
assessed risks of material misstatement due to fraud. We have addressed these issues in the
context of our audit of the separate financial statement as a whole and also when formulating
our opinion. We have also summarized our response to such risk types, and in cases where
we deemed it appropriate, we presented our key observations concerning these risk types.
We do not state a separate opinion in relation to these matters.
Key audit matter How does our audit address this matter?
R&D work
The Company conducts work in the field
of IT development related to the
business asset construed as the
DataWalk platform.
In its separate financial statement, the
Company recognizes costs of completed
development work at PLN 15 538 thous.
and costs of development work in
progress at PLN 3 574 thous., which
accounts in total for 46% of the balance
sheet total as at 31 December 2023.
Details on the capitalization of
expenditure on development work and
expenditure incurred in relation to
development work in progress (including
information on the results of the
conducted impairment test) described in
notes 2.1, 2.2, 2.3 and 2.4 of the
separate financial statement, and
related to the accounting policy, have
been described in the explanatory note
to the separate financial statement.
Our procedures to address an identified key
risk included, among others:
understanding and assessing the
process of identifying, accepting and
classifying development work
expenditure as intangible assets,
verifying compliance of the
Company’s accounting policy with IAS
38,
detailed reliability study associated
with the correct allocation of
development work expenditure,
assessing the developed impairment
tests in terms of mathematical
correctness, rationale behind the key
parameters adopted by the
Company, compliance of financial
projections with the approved
financial plan, and the sensitivity of
the test to a change in the assumed
level of cash flows and discount rate,